

## The Innovative Health Initiative EU's new partnership in health

Klelia D. Salpea, PhD Athens, 19. 04. 2024



## Public-private partnerships (PPPs) in health •

Addressing the increasingly complex challenges facing modern day healthcare requires joining forces to bridge the gaps between new knowledge, innovation and implementation of new solutions for patients in healthcare.

PPPs present unique opportunities for collaborative research:

- bring together different stakeholders not used to work together
- break silos
- leverage complementary expertise
- learn from each other
- pool together resources





## Innovative Medicines Initiative (IMI) 1 & 2

• The IMI1 and IMI2 programmes resulted in almost 200 projects covering a wide range of disease areas and addressing challenges across all areas of medical research and drug development.

• IMI projects have and continue to deliver impressive results that amply demonstrate the value of a PPP that brings together all stakeholders – universities, companies large and small, patients, regulators and others.



## **Innovative Health Initiative (IHI)**

IHI is a <u>neutral</u> platform that allows researchers, industries (large and small, different sectors), regulatory bodies, healthcare providers, healthcare professionals, patients, carers to work together

- Cross-sectorial collaboration are at the core of IHI projects
- IHI focus will be to go beyond medicines development and supports the translation of scientific progress, technology advances and opportunities of digitalisation to improve health care
  - Particular focus on the patient journey prevention, diagnosis, treatment and management of diseases/conditions

Research supported by IHI should remain at precompetitive level



### IHI EU's new partnership in health

European Union represented

by the European Commission (Horizon Europe Health Cluster)

up to EUR 1.2 billion

## Private members representing healthcare industry:

**COCIR** (medical imaging, radiotherapy, health ICT and electromedical industries)

**EFPIA**, including **Vaccines Europe** 

(pharmaceutical and vaccine industries)

EuropaBio (biotechnology industry)

**MedTech Europe** (medical technology industry)

at least EUR 1.0 billion

**EUR 2.4 billion** 





# Strategic Research and Innovation Agenda (SRIA)



## IHI Objectives

Improve our understanding of the factors that affect health and the treatment of priority disease areas

Integrate fragmented health research and innovation efforts by bringing together health industry sectors and other stakeholders to improve prevention, diagnosis, treatment, and management of diseases, focusing on unmet public health needs



Demonstrate the feasibility of **people-centred**, **integrated healthcare solutions** which draw on various technologies and sectors



Exploit the full potential of **digitalisation and data exchange** in research and care, while respecting **privacy** legislation



Develop methodologies for a comprehensive assessment of the added value of **innovative and integrated health care solutions** 



Deliver
safe, effective
health innovations
that cover the entire
spectrum of care,
particularly in areas
where there is an
unmet public health
need

By achieving these, IHI aims to Make Europe's health industries globally competitive

Turn health
research and
innovation into
real benefits for
patients and
society





## IHI projects:

Created via open and competitive Calls for proposals

Cross sectorial public private partnerships leveraging:

- Contributions from:
  - industries part of the IHI industry associations (EFPIA –including Vaccine Europe- COCIR, MedTechEurope, EuropaBio)
  - If relevant also from Contributing partners (must be approved by IHI GB)
- Public funding
  - Via European Commission (Horizon Europe funding)



## 2 types of calls for proposals

### single-stage

- Broad topic, not specific to one single product/technology/solution
- Private Members\* & contributing partners apply simultaneously with Public Members in mixed consortia
- Due to its openness and competitive character, <u>private members can receive</u> <u>funding</u>
- Pharma companies will abstain from requesting funding
- Industry partners build consortia with public partners (like in HE regular calls)
- Proposed budgets must include at least 45% in-kind/cash contribution (e.g., 10 mil total budget: at least 4.5 mil in-kind/cash provided by Private Members & contributing partners)


### 2-stage

- CROSS-SECTORIAL PUBLIC-PRIVATE PARTNERSHIPS
- Topics and budget are determined by Private Members (Pre-identified industry consortium)
- Applicant consortia of beneficiaries requesting funding submit a short proposal at stage 1
- The successful applicant consortium joins with the pre-identified industry consortium the second stage
- Pre-identified Industry consortium Members are not eligible for funding
- In fact, no funding will be made available for any company with annual turnover > 500M
- No requirement for applicant consortia to provide in-kind/cash contributions at the 1<sup>st</sup> stage of a two stage process




<sup>\*</sup>Please refer to https://www.ihi.europa.eu/sites/default/files/IHI\_Guide\_for\_Applicants.pdf

# How does IHI work? Single-stage procedure





## How IHI works: 2-stage calls





## Rules of Participation



## Eligibility rules: Participation





Any legal entity or international organisation regardless of its place of establishment



At least 3 independent legal entities established in a different

Member State or Associated Country





IHI specific eligibility criterion

NOT applicable: stage one of
two-stage calls:



1 legal entity should be established in a Member State



Costs related to contributions provided by participants shall amount to at least 45% of the total project cost.

IKOP, IKAA or FC



### Type of contributions from private members of IHI •

The private members of IHI JU are the private industry associations COCIR, EFPIA (including Vaccines Europe), EuropaBio and MedTech Europe.

The constituent and affiliated entities of the private members can provide three types of contributions to consortia implementing IHI JU projects:

- in-kind contributions to operational activities (IKOP) consist of the eligible costs for implementing the action;
- in-kind contributions to additional activities (IKAA) consist of costs for implementing additional activities;
- financial contribution (FC) consists of cash contributions to project beneficiary(ies) (or directly to IHI JU) to support the eligible costs incurred by the project beneficiary(ies) concerned in implementing the IHI JU action.

## Contributing Partners

Organisations that want to invest in IHI without becoming full members.

#### Who?

 Any country, international organisation or legal entity that wants to contribute to the IHI objectives can apply.

(exception: members / affiliates of IHI industry partners)

#### What?

 Contributing partners invest their own resources (staff time / laboratories / data / cash) in a specific IHI project(s).



# Eligibility rules: funding for single-stage Calls



Non-profit organisations

**Academics** 

Regulators

For-profit legal entities (SME and larger enterprises)

NGOs

**Patients' Organisations** 

**Public bodies** 

Hospitals

research organisations

intergovernmental organisations



Any legal entity established in a Member State, Associated Country or

**Low and Middle Income Countries** 



See Horizon Europe programme guide



# Eligibility rules: funding for two-stage Calls



Non-profit organisations

**Academic** institutions

For-profit legal entities
(SME and larger enterprises with an annual turnover of less than EUR 500 million)



Any legal entity established in a Member State, Associated Country or Low and Middle Income countries



See Horizon Europe programme guide



#### **NOT** eligible for funding:

- Pre-identified Industry Consortium
- Any legal entities which is:

- (a) A for-profit legal entity with an annual turnover of EUR 500 million or more
- (b) A for profit legal entity directly or indirectly controlling/or being controlled by for profit legal entities with an annual turnover of EUR 500 million or more.





## Open Calls



## IHI call 7 - single-stage




Apply for funding Shape our future research Projects and results Resources for projects News & events About IHI

Apply for funding > Open calls

### **Open calls**

Check out our calls that are open for full proposals (singlestage) or short proposals (two-stage).



IHI calls for proposals represent an opportunity for organisations involved in health research and healthcare to form consortia and apply to be part of cross-sector partnerships that bring together a range of stakeholders to tackle some of the biggest challenges in health research today.

On this page, we list calls that are open for full proposals (for single-stage calls) or short proposals (for two-stage calls).

IHI call 7

HI call 7 is a single-stage call with topics on heart disease, the healthcare workforce, and biomarker validation. Deadline for full proposals: 22 May 2024

Learn more about IHI call 7





## Call 7 – single stage

### **Topics**

- Topic 1: Improving clinical management of heart disease from early detection to treatment
- Topic 2: User-centric technologies and optimized hospital workflows for a sustainable healthcare workforce
- Topic 3: Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment response.

The submission deadline for full proposals (FPs) will be 22/05/2024.



## Apply to IHI calls

Keep an eye on our website for future call topics. Draft call topics are published on our website before the official launch of a call.

Read more about the topic ideas

www.ihi.europa.eu/apply-funding/future-opportunities



## How to find partners



## IHI calls—find out more & find partners

### You'll need to build or join a consortium!

- Sign up for our webinars on the call topics & our rules and procedures during the IHI Call days
- Look out for our brokerage event during the IHI Call days
- Use online partner search tools (e.g. on the Funding & Tenders portal, IHI B2Match platform)

More tips: <a href="https://example.com/linearing-new-to-sep-12">IHI Call Days - Home (b2match.io)</a>




### The b2match platform - step-by-step

**IHI Call Days** 

▼ How to find participants, send messages, and set up a meeting

 Identify promising participants on the Participants list or the Marketplace page on the event's website. Once you found a suitable meeting partner, click "Request meeting" to send them a meeting request.



## Shape our future research



## Send us your ideas for IHI projects

- Many ideas for call topics come from our partners (industry members and the European Commission) but we also welcome ideas from the wider health and research community.
- All ideas will have to demonstrate
  - how they would help IHI to achieve its goals;
  - how they are aligned with the IHI SRIA;
  - why they need a cross-sectoral public-private partnership.
- Ideas will be assessed by the IHI Programme Office and governance bodies.
- Follow the link: <u>propose your ideas</u>



### **Propose ideas**

Got an idea for a potential IHI call topic? We want to hear from you!



For transparency purposes, all ideas reviewed by the SIP are published here, along with a summary of the SIP opinion and the current status of the idea.

Reconciling the technical and legal requirements of the European Health Data Space Idea ref. 001169 | SIP opinion | Status: Not kept for consideration at this stage

Improved care pathways in Parkinson's disease through digital technologies
Idea ref. 001164 | SIP opinion | Status: Not kept for consideration at this stage

<u>Defining the temporal responsiveness of the gut microbiome to major diet and lifestyle interventions</u> Idea ref. 001160 | <u>SIP opinion</u> | Status: Not kept for consideration at this stage





Thank you for your attention

Klelia D. Salpea, PhD Scientific Officer











